Ľubomír Skladaný, Marian Oltman, Jozef Baláž, Jozef Květenský, Peter Jarčuška
Biologic therapy has gained considerable attention in Gastroenterology owing to its effectivity, and it therefore often reaches boundaries with Hepatology. Coexistence of inflammatory bowel disease with liver diseases is rather common and requires to be allowed for before the initiation of biologic therapy. None of the liver diseases represents an absolute contraindication to biologic therapy. Close attention should be paid to hepatitis B infection, where a consultation with a specialist in Hepatology or Infectious Diseases should be sought prior to the beginning of the therapy. Hepatitis C infection does not represent a serious threat, although parallel monitoring by a Hepatologist is recommended. Other respective liver diseases were even experimentally treated with biologic therapy and despite lack of positive findings, biologic therapy does not require any special measures from the hepatological point of care.